Latest Period
n/a
Security Snapshot
Forte Biosciences, Inc. - Common Stock, par value $0.001 per share (FBRX) Institutional Ownership
CUSIP: 34962G109
13F Institutional Holders and Ownership History from Q1 2019 to Q3 2024
Institutions Reporting
Shares (Excl. Options)
Price
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- FBRX on Nasdaq
- Shares outstanding
- 20,563,488
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- FBRX - Forte Biosciences, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 34962G109.
- Latest finished 13F holder period is not available.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 32 to 0 between Q2 2024 and Q3 2024.
- SEC-reported value moved from $10,228,138 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
34962G109
Latest holder period
n/a
13F holders
13D/G owners
5
CIK / CUSIP context first
FBRX full holder history
Forte Biosciences, Inc. SEC filings
Forte Biosciences, Inc. company facts
Forte Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 34962G109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
FBRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 7.3% | 1,011,890 | Affinity Asset Advisors, LLC | 31 Mar 2026 | ||||
| MPM BioImpact LLC | 7.2% | 1,000,682 | MPM BioImpact LLC | 31 Mar 2026 | ||||
| Adage Capital Management, L.P. | 6.8% | 950,000 | Adage Capital Management, L.P. | 31 Mar 2026 | ||||
| ORBIMED ADVISORS LLC | 4.3% | 884,230 | ORBIMED ADVISORS LLC | 31 Mar 2026 | ||||
| Farallon Capital Partners, L.P. | 3.4% | $12,130 | 221,027 | Dapice Joshua J. | 31 Dec 2024 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Latest
n/a
Rows shown
1-23 of 23
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2024 Q3 | 0 | $0 | -$10,134,239 | 0 | |
| 2024 Q2 | 19,046,477 | $10,228,138 | -$6,914 | $0.54 | 32 |
| 2024 Q1 | 19,048,634 | $13,285,300 | +$131,933 | $0.70 | 32 |
| 2023 Q4 | 18,862,822 | $15,499,549 | +$107,364 | $0.82 | 34 |
| 2023 Q3 | 16,699,691 | $11,053,360 | +$8,677,955 | $0.66 | 30 |
| 2023 Q2 | 3,463,993 | $3,601,147 | -$405,929 | $1.04 | 28 |
| 2023 Q1 | 3,865,337 | $3,904,404 | +$63,530 | $1.01 | 28 |
| 2022 Q4 | 3,801,902 | $3,800,654 | -$331,796 | $1.00 | 30 |
| 2022 Q3 | 2,668,691 | $2,852,110 | +$306,315 | $1.07 | 24 |
| 2022 Q2 | 2,308,331 | $3,001,130 | -$1,978,602 | $1.30 | 27 |
| 2022 Q1 | 3,886,365 | $5,675,151 | -$2,490,490 | $1.46 | 44 |
| 2021 Q4 | 5,360,245 | $11,473,214 | +$2,615,294 | $2.14 | 45 |
| 2021 Q3 | 3,861,588 | $11,432,424 | -$209,734,334 | $2.96 | 52 |
| 2021 Q2 | 8,609,574 | $289,376,415 | +$20,624,459 | $33.62 | 75 |
| 2021 Q1 | 7,968,324 | $273,111,000 | -$14,949,451 | $34.27 | 62 |
| 2020 Q4 | 8,392,546 | $305,570,000 | +$56,276,590 | $36.41 | 49 |
| 2020 Q3 | 6,803,921 | $330,057,000 | +$190,204,632 | $48.51 | 45 |
| 2020 Q2 | 2,883,976 | $42,049,000 | +$42,049,000 | $14.58 | 22 |
| 2020 Q1 | 66 | $2,000 | $30.30 | 1 | |
| 2019 Q4 | 66 | $2,000 | $30.30 | 1 | |
| 2019 Q3 | 66 | $2,000 | $30.30 | 1 | |
| 2019 Q2 | 66 | $2,000 | $30.30 | 1 | |
| 2019 Q1 | 66 | $2,000 | $30.30 | 1 |